Zheng‐Yi Zhou

机构：Health Economics and Outcomes Research (United Kingdom), Institute of Group Analysis, Hubei University of Technology, Analysis Group (United States) · ORCID：0000-0001-9014-8479

发表论文 168 篇 · 总被引 1798 次 · h-index 22

代表论文

Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (2025 · Clinical Lymphoma Myeloma & Leukemia · 被引 8)
Comparative Efficacy of linvoseltamab versus Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison (2025 · Clinical Lymphoma Myeloma & Leukemia · 被引 4)
Real-world clinical outcomes of cabozantinib as a second-line treatment for advanced hepatocellular carcinoma: a retrospective US claims analysis (2025 · The Oncologist · 被引 4)
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison (2026 · Leukemia & lymphoma/Leukemia and lymphoma · 被引 1)
Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): Updated matching-adjusted indirect comparison (MAIC) with longer follow-up. (2026 · Journal of Clinical Oncology · 被引 1)
Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma (2025 · Journal of Managed Care & Specialty Pharmacy · 被引 1)